Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Ugeskrift for Laeger|January 5, 2018
[Multicentric reticulohistiocytosis is a rare form of paraneoplasia]Anna Maria Anderson, Tanja Todberg, Kristian Kofoed, et al.
Neurobiology of Learning and Memory|July 19, 2011
A novel operant testing regimen for multi-construct cognitive characterization of a murine model of Alzheimer's amyloid-related behavioral impairmentAlice L Blackshear, Wenjin Xu, Maria Anderson, et al.
Methods (San Diego, Calif.)|July 11, 2006
Methods for reverse genetic screening in zebrafish by resequencing and TILLINGRaman Sood, Milton A English, MaryPat Jones, et al.
The Journal of Clinical Investigation|May 10, 2008
Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndromeMichael Brunner, Xuwen Peng, Gong Xin Liu, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Cancer Chemotherapy and Pharmacology|June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumorsColin D Weekes, Lee S Rosen, Anna Capasso, et al.
Frontiers in Oncology|November 16, 2016
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)Jérôme Fayette, Lori Wirth, Cristina Oprean, et al.
The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Pageof 3